KERENDIA’s payer coverage is stronger than ever for your patients with CKD associated with T2D

KERENDIA is COVERED on some of the largest Commercial and Medicare Part D formularies in the nation, covering over 150 million lives¹


There are 2 savings offers available to help your eligible patients start and stay on KERENDIA:

*Patients are eligible if they are commercially insured and may pay as little as $0 and save up to $3000 per year. Patients who are enrolled in any type of government insurance or reimbursement programs are not eligible. Full terms and conditions apply, see

Terms and conditions apply. Call 1-888-KERENDIA (537-3634) or visit for more information.

It is easy to get or activate a KERENDIA Savings Card or KERENDIA Free Trial Voucher.

Tell your patients to visit

Please provide the $0 KERENDIA Savings Card and/or KERENDIA Free Trial Voucher to your patients and instruct them to activate the card and take it to the pharmacy with their KERENDIA prescription.

Here are additional resources you may find helpful to gain patient access to KERENDIA:

    We are committed to helping your patients start KERENDIA by supporting their insurance and affordability challenges

    Access Services by Bayer is working with CoverMyMeds® to provide the support your patients count on, with enhanced services you can trust from CoverMyMeds®.

    We provide visibility into the entire patient journey and reduce time to therapy through enhanced services within your workflow:

    • Electronic Benefits Verification (eBV), Benefits Investigation (preliminary)
    • Electronic Prior Authorization (ePA) (preliminary)
    • Appeals support

    Log in to or create your account at to help your patients start KERENDIA today.

    Patients who need help paying for their KERENDIA prescription should call 1-888-KERENDIA (537-3634) or visit to learn more about the affordability solutions offered by Bayer.

    CoverMyMeds® is an independent party.

    You may also contact Access Services by Bayer for support at 1-800-288-8374

    Do you have a patient who needs additional assistance?

    Logo Bayer US Patient Assistance Foundation

    The Bayer US Patient Assistance Foundation is a charitable organization that helps eligible patients get their Bayer prescription medicine at no cost. Please have your patient contact the program at 1-866-2BUSPAF (228-7723) Monday–Friday, 9:00 am–6:00 pm EST, or visit the foundation website at to see if they might qualify for assistance.


    KERENDIA is indicated to reduce the
    risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)



    • Concomitant use with strong CYP3A4 inhibitors
    • Patients with adrenal insufficiency


    • Hyperkalemia: KERENDIA can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia. Measure serum potassium and eGFR in all patients before initiation of treatment with KERENDIA and dose accordingly. Do not initiate KERENDIA if serum potassium is >5.0 mEq/L


      Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium


    • From the pooled data of 2 placebo-controlled studies, the adverse reactions reported in ≥1% of patients on KERENDIA and more frequently than placebo were hyperkalemia (14% vs 6.9%), hypotension (4.6% vs 3.9%), and hyponatremia (1.3% vs 0.7%)


    • Strong CYP3A4 Inhibitors: Concomitant use of KERENDIA with strong CYP3A4 inhibitors is contraindicated. Avoid concomitant intake of grapefruit or grapefruit juice
    • Moderate and Weak CYP3A4 Inhibitors: Monitor serum potassium during drug initiation or dosage adjustment of either KERENDIA or the moderate or weak CYP3A4 inhibitor and adjust KERENDIA dosage as appropriate
    • Strong and Moderate CYP3A4 Inducers: Avoid concomitant use of KERENDIA with strong or moderate CYP3A4 inducers


    • Lactation: Avoid breastfeeding during treatment with KERENDIA and for 1 day after treatment
    • Hepatic Impairment: Avoid use of KERENDIA in patients with severe hepatic impairment (Child Pugh C) and consider additional serum potassium monitoring with moderate hepatic impairment (Child Pugh B)

    Please read the Prescribing Information for KERENDIA.

    References: 1. Data on file. Bayer.